AKRO
Akero Therapeutics Inc
NASDAQ: AKRO · HEALTHCARE · BIOTECHNOLOGY
$54.65
+0.00% today
Updated 2025-12-09
Market cap
$4.50B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.75
Dividend yield
—
52W range
$32 – $57
Volume
2.9M
Akero Therapeutics Inc (AKRO) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $658000.00 | $77.15M | $138.12M | $273.34M | $195.55M | $356.57M | $580.27M | $825.89M |
| Cash & equivalents | $598000.00 | $75.97M | $64.79M | $187.24M | $150.48M | $249.77M | $234.21M | $340.24M |
| Current assets | $638000.00 | $77.13M | $138.05M | $271.35M | $193.58M | $355.17M | $559.96M | $770.38M |
| Total liabilities | $5.22M | $127.07M | $9.39M | $14.63M | $26.44M | $30.01M | $44.97M | $75.77M |
| Current liabilities | $222000.00 | $2.34M | $9.37M | $13.11M | $25.13M | $19.08M | $19.13M | $39.75M |
| Long-term debt | $0.00 | $0.00 | — | — | — | $9.54M | $24.96M | $35.30M |
| Shareholder equity | $-4.56M | $-49.92M | $128.73M | $258.71M | $169.11M | $326.56M | $535.31M | $750.11M |
| Retained earnings | $-4.56M | $-86.56M | $-130.32M | $-209.53M | $-310.30M | $-422.34M | $-574.10M | $-826.16M |
| Accounts receivable | — | — | — | $201000.00 | $417000.00 | — | — | — |
| Inventory | $0.00 | $0.00 | — | — | — | — | — | — |
| Goodwill | $0.00 | $0.00 | — | — | — | — | — | — |